Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Teprotumumab

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amgen 1Q Results
    Amgen 1Q Results

    21 May 2024

    // CONTRACT PHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2024-05-21/amgen-1q-results/?widget=listSection

    CONTRACT PHARMA
    21 May 2024
    Share Share
    AMGEN to Submit Teprotumumab MAA to EMA
    AMGEN to Submit Teprotumumab MAA to EMA

    26 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/amgen-to-submit-teprotumumab-marketing-authorization-application-to-the-european-medicines-agency-302128358.html

    PR NEWSWIRE
    26 Apr 2024
    Share Share
    Amgen reports 3rd straight sequential sales increase for Tepezza
    Amgen reports 3rd straight sequential sales increase for Tepezza

    07 Feb 2024

    // Kevin Dunleavy FIERCE PHARMA

    https://www.fiercepharma.com/pharma/amgen-expects-revenue-bump-its-acquisition-horizon-between-324b-and-338b

    Kevin Dunleavy FIERCE PHARMA
    07 Feb 2024
    Share Share
    Analysis Highlights Adhering to Uninterrupted Full Course with TEPEZZA
    Analysis Highlights Adhering to Uninterrupted Full Course with TEPEZZA

    29 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230929700356/en

    BUSINESSWIRE
    29 Sep 2023
    Share Share
    Horizon adds 'severe hearing impairment' warning to blockbuster's label
    Horizon adds 'severe hearing impairment' warning to blockbuster's label

    20 Jul 2023

    // Zachary Brennan ENDPTS

    https://endpts.com/horizon-adds-severe-hearing-impairment-warning-to-blockbusters-label/

    Zachary Brennan ENDPTS
    20 Jul 2023
    Share Share
    Horizon's Biologic Tepezza(teprotumumab) Receives Approval in the U.S.
    Horizon's Biologic Tepezza(teprotumumab) Receives Approval in the U.S.

    17 Jul 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761143

    FDA
    17 Jul 2023
    Share Share